Dr. Kiran Turaga on Advancements in Classification, Imaging in Sarcoma

Kiran Turaga, MD, MPH
Published: Wednesday, Oct 12, 2016


Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses advancements in the field of sarcoma.
 
Both phylogeneticaly and evolutionarily sarcomas can now be classified into broad groups.
 
They used to be classified by histology; if they are more like muscles or rhabdomyosarcoma, or they are more like fats or liposarcomas. However, it is now understood that there are certain groups of sarcomas that are closer to each other, versus certain groups of sarcomas that are further apart, says Turaga. By grouping these tumors together, it is easier to understand how to treat them.
 
There have also been advances in imaging, especially diffusion-weighted imaging for retroperitoneal sarcomas, says Turaga.
 
Diffusion-weighted imaging relies on the water content of cells and improves the ability to detect some areas of malignancy and potentially guide biopsies and pretreatment paradigms.
 

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discusses advancements in the field of sarcoma.
 
Both phylogeneticaly and evolutionarily sarcomas can now be classified into broad groups.
 
They used to be classified by histology; if they are more like muscles or rhabdomyosarcoma, or they are more like fats or liposarcomas. However, it is now understood that there are certain groups of sarcomas that are closer to each other, versus certain groups of sarcomas that are further apart, says Turaga. By grouping these tumors together, it is easier to understand how to treat them.
 
There have also been advances in imaging, especially diffusion-weighted imaging for retroperitoneal sarcomas, says Turaga.
 
Diffusion-weighted imaging relies on the water content of cells and improves the ability to detect some areas of malignancy and potentially guide biopsies and pretreatment paradigms.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x